Youngone Corporation Surges Over 11% on Strong Q3 Results

The stock price of Youngone Corporation, which announced better-than-expected results for the third quarter of this year, is showing strong performance. Youngone Corporation is a global apparel brand OEM (original equipment manufacturer) company that handles brands such as The North Face and Lululemon. As of 9:28 a.m. on the 17th, Youngone Corporation was trading at 77,000 won, up 7,800 won (11.27%) from the previous trading day. In the third quarter, Youngone Corporation recorded consolidated sales of 1.2047 trillion won and operating profit of 181.2 billion won. These figures represent increases of 12.8% and 73.4%, respectively, compared to the same period last year, significantly exceeding the market consensus. On this day, DB Financial Investment maintained its buy rating on Youngone Corporation and raised its target price from 70,000 won to 95,000 won. Heajana, a researcher at DB Financial Investment, explained, "OEM dollar sales grew by 11% compared to the same period last year,"

Notable Stocks

11.17 09:29

Isu Petasys Soars as Brokerages Raise Target Prices

On November 17, Isu Petasys surged more than 13% in early trading. Investor sentiment appears to have recovered as major securities firms simultaneously raised their target prices. As of 9:19 a.m. on the same day, Isu Petasys shares were trading at 125,900 won on the Korea Exchange, up 13.32% compared to the previous trading day. The stock opened at 117,900 won and continued to climb. At one point during the session, it soared to 127,900 won, marking a new 52-week high. On this day, Park Hyungwoo, a researcher at SK Securities, stated, "Isu Petasys has significant upside momentum for its stock price next year, and with rising demand for new artificial intelligence (AI) accelerator products, further improvements in profitability and stock price increases are expected." He maintained a 'Buy' rating and raised the target price to 144,000 won. Kiwoom Securities also raised its target price to 140,000 won, forecasting that the company will continue its high growth trajectory as increased pr

Notable Stocks

11.17 09:26

Daewoong Pharmaceutical Surges Over 9% on News of Diabetes Drug Export to Central and South America

Daewoong Pharmaceutical is showing a strong performance on November 14, rising by over 9% following news of an export contract for its diabetes treatment to Central and South America. As of 10:39 a.m. on this day, shares of Daewoong Pharmaceutical were trading at 177,400 won on the Korea Exchange, up 9.04% from the previous trading day. The stock opened at 160,200 won and at one point during the session soared to 181,400 won, setting a new 52-week high. On this day, Daewoong Pharmaceutical announced that it had signed an export contract for its diabetes drug, Enblo Tab, with eight countries in Central and South America. The contract is valued at approximately 33.7 billion won, and when combined with existing contracts, the total amounts to about 143.3 billion won. As a result, Enblo Tab has now entered a total of 10 Central and South American countries, including Brazil and Mexico. Enblo Tab is the 36th new drug developed with domestic technology and is the first sodium-glucose cotrans

Notable Stocks

11.14 10:44

Hansae Rises 4% as Securities Firms Raise Target Price After Overcoming Tariff Hurdle

Hansae Co., Ltd. is showing strong performance in early trading on November 14. This is due to securities firms raising their target price for Hansae, diagnosing that the company has passed its bottom. As of 9:38 a.m. on this day, Hansae is trading at 12,560 won, up 490 won (4.06%) from the previous trading day. Until the previous day, Hansae had risen for seven consecutive trading days, as it posted solid results in the third quarter despite tariff pressures. On this day, securities firms raised their target price for Hansae. NH Investment & Securities evaluated that the downward revision of Hansae's earnings has been completed and the valuation has bottomed out, raising its investment opinion from 'Hold' to 'Buy' and increasing the target price from 11,000 won to 15,000 won. Jung Ji-yoon, a researcher at NH Investment & Securities, stated, "We have confirmed that the company's performance in the second half of the year is solid compared to our conservatively estimated sales forecast,

Notable Stocks

11.14 09:46

"100,000-won Samsung" and "600,000-won Hynix" Break Down... Impact from U.S. Tech Stock Plunge

The share prices of Samsung Electronics and SK Hynix showed weakness in the early session on November 14. This is attributed to the sharp decline in technology stocks on the New York Stock Exchange overnight, driven by renewed concerns over an artificial intelligence (AI) bubble. As of 9:25 a.m. on this day, Samsung Electronics was trading at 99,400 won, down 3.31% from the previous session, breaking below the so-called “100,000-won mark.” SK Hynix saw an even steeper drop of over 5%, trading at 581,000 won, down 5.07%. Both stocks had already fallen below the 100,000-won and 600,000-won levels, respectively, during pre-market trading. Overnight, all three major U.S. stock indices closed lower, despite the end of the U.S. federal government shutdown. This decline was attributed to subsequent uncertainty in economic indicators and hawkish comments from key Federal Reserve officials. In particular, the tech-heavy Nasdaq index fell 2.29% from the previous session, and this impact is being

Notable Stocks

11.14 09:36

Seers Technology Surges on Strong Q3 Earnings

As of 9:20 a.m. on November 14, shares of Seers Technology on the KOSDAQ market were trading at 120,000 won, up 20% from the previous day's closing price. The stock has been hitting record highs for several consecutive days, and this surge appears to be driven by the company's strong third-quarter results announced on the same day, which increase the likelihood that it will become the first domestic company in the medical AI sector to achieve an annual profit. On this day, Seers Technology disclosed through its quarterly report that it posted third-quarter revenue of 15.7 billion won and operating profit of 6.8 billion won. Compared to the same period last year, revenue jumped by 1,500% (from 980 million won), and operating profit turned positive from a loss of 3.5 billion won. Even compared to the second quarter of this year, when the company first recorded a quarterly profit, revenue and operating profit increased by 98% and 357%, respectively. As a result, Seers Technology has achie

Notable Stocks

11.14 09:25

Senatechnology Surges Over 160% on First Day of KOSDAQ Listing

Senatechnology is experiencing a surge of over 160% on its first day of trading on KOSDAQ. As of 9:11 a.m. on November 14, Senatechnology was trading at 150,700 won, up 93,900 won (165.32%) from its initial public offering price of 56,800 won. Senatechnology finalized its IPO price at the top end of its target range, 56,800 won, after recording a competition rate of 976.9 to 1 in the institutional investor demand forecast conducted from October 23 to 29. In the general subscription held on November 4 and 5, the competition rate was 885 to 1. The subscription deposit amounted to approximately 3.5 trillion won. Founded in 1998, Senatechnology is the global leader in the motorcycle team communication market. It has been selected as the Best Brand in the communication systems category for seven consecutive years by Motorrad, a German motorcycle magazine with a 120-year history.

Notable Stocks

11.14 09:18

Lunit Drops on Concerns Over Widening Losses

As of exactly 2:00 p.m. on November 13, 2025, shares of the AI bio company Lunit were trading at 39,425 won on the KOSDAQ market, down 16.65% from the previous day's closing price. This appears to be due to concerns that the timeline for turning a profit will be delayed as the company's losses have continued to grow year after year. Lunit generates revenue through its flagship AI cancer diagnosis platform "Lunit Insight," its AI cancer treatment biomarker platform "Lunit Scope," and its wholly owned subsidiary "Volpara." According to the consolidated financial statements, Lunit's revenue (operating income) was 25.1 billion won in 2023, 54.2 billion won in 2024, and 56.7 billion won as of the end of the third quarter this year. However, operating losses also increased, reaching 42.2 billion won in 2023 and 67.9 billion won in 2024. By the end of the third quarter this year, the operating loss stood at 63.5 billion won, with annual losses expected to approach 80 billion won. Previously,

Notable Stocks

11.13 14:01

Yellow Balloon Up 12% on Hopes of Domestic Travel Gains Amid China-Japan Tensions

Youngone Corporation Surges Over 11% on Strong Q3 Results

Isu Petasys Soars as Brokerages Raise Target Prices

Daewoong Pharmaceutical Surges Over 9% on News of Diabetes Drug Export to Central and South America

Hansae Rises 4% as Securities Firms Raise Target Price After Overcoming Tariff Hurdle

"100,000-won Samsung" and "600,000-won Hynix" Break Down... Impact from U.S. Tech Stock Plunge

Seers Technology Surges on Strong Q3 Earnings

Senatechnology Surges Over 160% on First Day of KOSDAQ Listing

Lunit Drops on Concerns Over Widening Losses

Special Coverage

In the News